Use of central neuromodulators in IBS

Investigators have examined the role and use of central neuromodulators — such as antidepressants, or antianxiety or antipsychotic medications — in treating patients with irritable bowel syndrome or IBS, according to a study published in The American Journal of Gastroenterology.

The investigators found that the agents enhanced synaptic transmission of serotonin, noradrenalin and dopamine; regulated the gut-brain axis and addressed psychiatric comorbidities, gut motility issues, visceral signal downregulation and neurogenesis enhancement. Selection of central neuromodulators were dependent on the patients’ predominant symptoms and bowel habits. The investigators noted that clinical responses were observed within six to eight weeks of treatment; however, long-term treatment was often required to prevent relapse.

They concluded that central neuromodulators may help patients with IBS manage both gastrointestinal and psychiatric symptoms. Further studies are needed to validate the findings.

Read more: The American Journal of Gastroenterology

The article presented here is intended to inform you about the broader media perspective on dentistry, regardless of its alignment with the ADA's stance. It is important to note that publication of an article does not imply the ADA's endorsement, agreement, or promotion of its content.